ArriVent BioPharma Future Growth
Future criteria checks 0/6
ArriVent BioPharma is forecast to grow earnings and revenue by 14.3% and 74% per annum respectively while EPS is expected to grow by 27.1% per annum.
Key information
14.3%
Earnings growth rate
27.1%
EPS growth rate
| Biotechs earnings growth | 28.6% |
| Revenue growth rate | 74.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 11 Sep 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 13 | -105 | -88 | N/A | 3 |
| 12/31/2025 | N/A | -101 | -94 | -98 | 3 |
| 12/31/2024 | N/A | -87 | -92 | -85 | 3 |
| 6/30/2024 | N/A | -75 | -68 | -68 | N/A |
| 3/31/2024 | N/A | -75 | -58 | -58 | N/A |
| 12/31/2023 | N/A | -69 | -56 | -56 | N/A |
| 9/30/2023 | N/A | -59 | -57 | -57 | N/A |
| 6/30/2023 | N/A | -56 | -51 | -51 | N/A |
| 3/31/2023 | N/A | -42 | -52 | -52 | N/A |
| 12/31/2022 | N/A | -37 | -44 | -44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVBP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AVBP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AVBP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AVBP is forecast to have no revenue next year.
High Growth Revenue: AVBP is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVBP's Return on Equity is forecast to be high in 3 years time